



Entrez PubMed

EXHIBIT 1

JAN 09 2007

Page 1 of 1



 A service of the National Library of Medicine
and the National Institutes of Health

[My NCBI](#)
[\[Sign In\]](#) [\[Register\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

Display Show Sort by Send to

All: 1 Review: 0 ☒

☐ 1: [Clin Appl Thromb Hemost](#). 2001 Jul;7(3):209-13.

[Links](#)

Individual dosing of ASA prophylaxis by controlling platelet aggregation.

Syrbe G, Redlich H, Weidlich B, Ludwig J, Kopitzsch S, Gockelfitz A, Herzog T.

Department of Internal Medicine, District Hospital of
Stadtroda/Thuringia, Germany. helgeredlich@t-online.de

Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic acid necessary to inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% of all patients studied, a dose of 30 mg/day was sufficient to block the arachidonic acid-induced platelet aggregation nearly completely. In 50% of all patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose had to be further increased to 300 mg/day or even to 500 mg/day to inhibit platelet aggregation nearly completely. These results demonstrate that platelet aggregation can be used as a simple routine laboratory method to control acetylsalicylic treatment in patients with cardiovascular diseases and to determine individual doses of acetylsalicylic acid for a nearly complete inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of the patients were nonresponders.

PMID: 11441981 [PubMed - indexed for MEDLINE]

Display Show Sort by Send to

[Write to the Help Desk](#)
[NCBI | NLM | NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Related Links

In vitro bleeding test with PFA-100- aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. [J Thromb Thrombolysis. 2001]

[Acetylsalicylic acid (ASA) resistance in patients with Ischemic heart disease (IHD) as bioindicator of the treatment strategy] [Cas Lek Cesk. 2005]

Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. [Eur J Clin Pharmacol. 1998]

Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers. [Cerebrovasc Dis. 2005]

Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. [Thromb Res. 2004]

See all Related Articles...

Dec 18 2006 06:34:27

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPl> 1/2/2007